Accelr8 and Schott Nexterion Announce Supply Agreement and Letter Of Intent For Exclusive License

    DENVER, Oct. 15 /PRNewswire-FirstCall/ -- Accelr8 Technology Corporation
 (Amex:   AXK) and SCHOTT Nexterion AG (Mainz, Germany) announced today the
 signing of a supply agreement and a letter of intent to proceed to an
 exclusive technology transfer license for Accelr8's OptiChem(TM) surface
 chemistry products.  Under the supply agreement, SCHOTT Nexterion will
 purchase Accelr8's OptArray(TM) microarraying slides and re-sell them under
 the Nexterion brand through its global sales organization starting
 immediately.  Under the intended technology transfer license, SCHOTT Nexterion
 will manufacture the OptArray slides and have exclusive global marketing
 rights to these products.  The two companies will cooperatively market the
 products, and Accelr8 will provide technology transfer consulting services to
 facilitate the transition.
     Accelr8 will be SCHOTT Nexterion's sole supplier of permeable hydrogel
 microarraying slides during the term of the supply agreement.  Accelr8 will
 provide sales training and will provide technical support to SCHOTT
 Nexterion's customers.  Accelr8's microarraying slides complement SCHOTT
 Nexterion's existing product range by providing a permeable three-dimensional
 hydrogel surface for high-performance applications in basic research, drug
 discovery, and molecular diagnostics.  During the term of the supply agreement
 Accelr8 will continue to produce the microarraying products in its Denver
 facility.  It is intended that SCHOTT Nexterion will ultimately become the
 exclusive outsource manufacturer for OptArray products in the Summer of 2004.
 Accelr8 will use exclusively SCHOTT's borosilicate glass in its slides, as it
 optimally complements the performance of the OptiChem surface chemistry.
     Thomas Geimer, Accelr8's Chairman and CEO said "This agreement represents
 the first step in fulfilling our objective of licensing our proprietary
 technologies to microarray market leaders.  SCHOTT Nexterion has aggressively
 entered the microarray market through strategic investments and acquisitions.
 They are the type of partner we've been seeking to help drive the next phase
 of microarray market evolution with our enabling technologies.  This
 relationship will leverage our proven product superiority in the DNA array
 market and build the foundation for protein arraying."
     According to Dr. Dirk van den Broek, CEO of SCHOTT Nexterion, "We are very
 pleased to adopt Accelr8's hydrogel technology at this critical juncture in
 the DNA microarraying market.  We intend to address the growing interest in
 improving microarray reproducibility and data quality.  Our scientists have
 confirmed the superior consistency and signal-to-noise performance that
 OptiChem coatings can deliver, and so we believe that this technology puts us
 in position to advance microarrays to their next level."
     Geimer noted "The intended license also validates our business model of
 licensing our technologies into partnerships with market leaders.  The license
 will allow us to focus on expanding OptiChem's capabilities.  In addition we
 will be able to commit more of our resources to the next generation of
 detection platforms that we believe can replace fluorescence detection."
 
     About Accelr8 Technology.
     Accelr8 Technology Corporation ( www.accelr8.com ) is a developer of
 innovative materials and instrumentation for advanced bio-analytical
 applications in basic research, drug discovery, molecular diagnostics, and
 pathogen detection for bio-defense and food safety.  The company sells
 OptArray(TM) microarraying slides and OptiPlate(TM) multiplexed arrayable
 microtiter plates. It is also developing advanced detection instrumentation
 based on its QuanDx(TM) and YoDx(TM) array processing and detection
 technologies.
 
     About SCHOTT Nexterion.
     SCHOTT Nexterion AG ( www.schott.com/nexterion ), a wholly owned
 subsidiary of SCHOTT, is specialized in high quality microarray solutions.  As
 such, the company develops and markets a wide range of coated and uncoated
 glass substrates for DNA and protein microarraying.  SCHOTT Nexterion
 continuously expands its product portfolio and has several innovative products
 and services in the development pipeline.  SCHOTT is an international
 technology-driven group and has 19,500 employees producing worldwide sales of
 2 billion euros.
 
     Certain statements in this news release may be "forward-looking
 statements" within the meaning of Section 27A of the Securities Act of 1933,
 as amended, and Section 21E of the Securities Exchange Act of 1934, as
 amended.  Statements regarding future prospects and developments are based
 upon current expectations and involve certain risks and uncertainties that
 could cause actual results and developments to differ materially from the
 forward-looking statement, including those detailed in the company's filings
 with the Securities and Exchange Commission.
 
 

SOURCE  Accelr8 Technology Corporation